Cost-effectiveness of prophylaxis with palivizumab among high-risk children in Hong Kong: abridged secondary publication
P Wu1, BJ Cowling1, SS Chiu2, IOL Wong1, WKY Yeung3
1 School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
3 Department of Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China
- Prophylaxis with palivizumab administered after start of respiratory syncytial virus seasons identified by moving epidemic method (ie, one-peak seasons typically starting in April and ending in October or later) was the most cost-effective strategy when used for infants with congenital heart disease and Down syndrome or extreme preterm delivery with bronchopulmonary dysplasia.
- Our findings can provide insights into further investigations concerning long-lasting monoclonal antibodies and vaccines.